Syncona-backed biotech launches in bid to shield heart cells from heart attacks
There have not been too many biotechs explicitly focused on cardiology.
While many have at least made some effort in the space, it is normally …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
